Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Elderly Advanced NSCLC
NCT00553800Phase 2Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2007
- Primary completion
- Jan 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Fox Chase Cancer Center. Primary endpoint: Progression Free Survival at 3 years. Started Jul 2007; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00553800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553800.